HLA-DR Recombinant Rabbit Monoclonal Antibody [SC06-78]
Usd: 205 Special Discount
Specification
Safety datasheet
Select your chosen country/region
- MSDS_HUABIO.pdf
- MSDS_HUABIO.pdf
- MSDS_ET1610-66_Europe.pdf
- No MSDS Found
Overview
Product Name
HLA-DR Recombinant Rabbit Monoclonal Antibody [SC06-78]
Antibody Type
Recombinant Rabbit monoclonal Antibody
Immunogen
Synthetic peptide within Human HLA-DRA aa 159-195 (Extracellular).
Species Reactivity
Human
Validated Applications
WB, IF-Cell, IHC-P
Target Molecular Weight
Predicted band size: 29 kDa
Positive Control
Daudi cell lysates, Raji cell lysates, Hela, human tonsil tissue, human liver tissue, human spleen tissue, Jurkat.
Conjugation
unconjugated
Clone Number
SC06-78
RRID
Reactivity Data
Tested Verified (internally validated)
Published Reported in literature (not internally validated)
Predicted Predicted reactive (based on sequence homology)
Not recommended Not recommended (failed internal validation)
| WB | IF-Cell | IHC-P | |
|---|---|---|---|
| Human |
|
|
|
| Mouse |
|
||
| Rat |
|
Product Features
Form
Liquid
Concentration
1 mg/mL.(The concentration of this product may be batch-dependent)
Storage Instructions
Shipped at 4℃. Store at +4℃ short term (1-2 weeks). Store at -20℃ long term.
Storage Buffer
1*PBS (pH7.4), 0.1% BSA, 40% Glycerol, 0.2% Proclean 950.
Isotype
IgG
Purification Method
Protein A affinity purified.
Application Dilution
-
WB
-
1:1,000
-
IF-Cell
-
1:50-1:200
-
IHC-P
-
1:50-1:200
Target
Function
Major histocompatibility complex (MHC) class II molecules destined for presentation to CD4+ helper T cells is determined by two key events. These events include the dissociation of class II-associated invariant chain peptides (CLIP) from an antigen binding groove in MHC II α/β dimers through the activity of MHC molecules HLA-DM and -DO, and subsequent peptide antigen binding. Accumulating in endosomal/lysosomal compartments and on the surface of B cells, HLA-DM, -DO molecules regulate the dissociation of CLIP and the subsequent binding of exogenous peptides to HLA class II molecules (HLA-DR, -DQ and -DP) by sustaining a conformation that favors peptide exchange. RFLP analysis of HLA-DM genes from rheumatoid arthritis (RA) patients suggests that certain polymorphisms are genetic factors for RA susceptibility. HLA-B belongs to the HLA class I heavy chain paralogs. Class I molecules play a central role in the immune system by presenting peptides derived from the endoplasmic reticulum lumen. HLA-B and -C can form heterodimers consisting of a membrane anchored heavy chain and a light chain (β-2-Microglobulin). Polymorphisms yield hundreds of HLA-B and -C alleles.
Background References
1. Mastropasqua R et al. Corneoscleral limbus in glaucoma patients: in vivo confocal microscopy and immunocytological study. Invest Ophthalmol Vis Sci 56:2050-8 (2015).
2. Wang H et al. CD68(+)HLA-DR(+) M1-like macrophages promote motility of HCC cells via NF-kB/FAK pathway. Cancer Lett 345:91-9 (2014).
Sequence Similarity
Belongs to the MHC class II family.
Post-translational Modification
Ubiquitinated by MARCH1 or MARCH8 at Lys-244 leading to down-regulation of MHC class II. When associated with ubiquitination of the beta subunit of HLA-DR: HLA-DRB4 'Lys-254', the down-regulation of MHC class II may be highly effective.
Subcellular Location
Cell membrane, Endoplasmic reticulum membrane, Golgi apparatus, Endosome membrane, Lysosome membrane.
UNIPROT
Synonyms
DR alpha chain antibody
DR alpha chain precursor antibody
DRA_HUMAN antibody
DRB1 antibody
DRB4 antibody
Histocompatibility antigen HLA DR alpha antibody
HLA class II histocompatibility antigen antibody
HLA class II histocompatibility antigen DR alpha chain antibody
HLA DR1B antibody
HLA DR3B antibody
ExpandDR alpha chain antibody
DR alpha chain precursor antibody
DRA_HUMAN antibody
DRB1 antibody
DRB4 antibody
Histocompatibility antigen HLA DR alpha antibody
HLA class II histocompatibility antigen antibody
HLA class II histocompatibility antigen DR alpha chain antibody
HLA DR1B antibody
HLA DR3B antibody
HLA DRA antibody
HLA DRA1 antibody
HLA DRB1 antibody
HLA DRB3 antibody
HLA DRB4 antibody
HLA DRB5 antibody
HLA-DRA antibody
HLADR4B antibody
HLADRA1 antibody
HLADRB antibody
Major histocompatibility complex class II DR alpha antibody
Major histocompatibility complex class II DR beta 1 antibody
Major histocompatibility complex class II DR beta 3 antibody
Major histocompatibility complex class II DR beta 4 antibody
Major histocompatibility complex class II DR beta 5 antibody
MGC117330 antibody
MHC cell surface glycoprotein antibody
MHC class II antigen DRA antibody
MHC II antibody
MLRW antibody
CollapseImages
-
Western blot analysis of HLA-DR on different lysates with Rabbit anti-HLA-DR antibody (ET1610-66) at 1/1,000 dilution.
Lane 1: Daudi cell lysate
Lane 2: Raji cell lysate
Lysates/proteins at 20 µg/Lane.
Predicted band size: 29 kDa
Observed band size: 35 kDa
Exposure time: 1 minute 40 seconds;
4-20% SDS-PAGE gel.
Proteins were transferred to a PVDF membrane and blocked with 5% NFDM/TBST for 1 hour at room temperature. The primary antibody (ET1610-66) at 1/1,000 dilution was used in 5% NFDM/TBST at 4℃ overnight. Goat Anti-Rabbit IgG - HRP Secondary Antibody (HA1001) at 1:100,000 dilution was used for 1 hour at room temperature. -
Immunocytochemistry analysis of Hela cells labeling HLA-DR with Rabbit anti-HLA-DR antibody (ET1610-66) at 1/50 dilution.
Cells were fixed in 4% paraformaldehyde for 10 minutes at 37 ℃, permeabilized with 0.05% Triton X-100 in PBS for 20 minutes, and then blocked with 2% negative goat serum for 30 minutes at room temperature. Cells were then incubated with Rabbit anti-HLA-DR antibody (ET1610-66) at 1/50 dilution in 2% negative goat serum overnight at 4 ℃. Goat Anti-Rabbit IgG H&L (iFluor™ 488, HA1121) was used as the secondary antibody at 1/1,000 dilution. PBS instead of the primary antibody was used as the secondary antibody only control. Nuclear DNA was labelled in blue with DAPI. -
Immunohistochemical analysis of paraffin-embedded human tonsil tissue using anti-HLA-DR antibody. The section was pre-treated using heat mediated antigen retrieval with Tris-EDTA buffer (pH 9.0) for 20 minutes.The tissues were blocked in 5% BSA for 30 minutes at room temperature, washed with ddH2O and PBS, and then probed with the primary antibody (ET1610-66, 1/200) for 30 minutes at room temperature. The detection was performed using an HRP conjugated compact polymer system. DAB was used as the chromogen. Tissues were counterstained with hematoxylin and mounted with DPX.
-
Immunohistochemical analysis of paraffin-embedded human liver tissue with Rabbit anti-HLA-DR antibody (ET1610-66) at 1/1,000 dilution.
The section was pre-treated using heat mediated antigen retrieval with Tris-EDTA buffer (pH 9.0) for 20 minutes. The tissues were blocked in 1% BSA for 20 minutes at room temperature, washed with ddH2O and PBS, and then probed with the primary antibody (ET1610-66) at 1/1,000 dilution for 1 hour at room temperature. The detection was performed using an HRP conjugated compact polymer system. DAB was used as the chromogen. Tissues were counterstained with hematoxylin and mounted with DPX. -
Immunohistochemical analysis of paraffin-embedded human spleen tissue using anti-HLA-DR antibody. The section was pre-treated using heat mediated antigen retrieval with Tris-EDTA buffer (pH 9.0) for 20 minutes.The tissues were blocked in 5% BSA for 30 minutes at room temperature, washed with ddH2O and PBS, and then probed with the primary antibody (ET1610-66, 1/200) for 30 minutes at room temperature. The detection was performed using an HRP conjugated compact polymer system. DAB was used as the chromogen. Tissues were counterstained with hematoxylin and mounted with DPX.
Citation
-
Perioperative tislelizumab plus chemotherapy for locally advanced gastric cancer: A randomized, prospective phase 2 trial
Journal: Cancer Cell
DOI: 10.1016/j.ccell.2026.06.015
IF: 56.1
Application: IHC-P
Reactivity: Human
Publish date: 2026 Jul
-
Single-cell analysis identifies PI3+S100A7+ keratinocytes in early cervical squamous cell carcinoma with HPV infection
Journal: Chinese Medical Journal
DOI: 10.1097/CM9.0000000000003795
IF: 7.3
Application: mIHC
Reactivity: Human
Publish date: 2025 Sept
-
Low Indoleamine 2,3-Dioxygenase 1 Expression Enhances Dendritic Cells Response to Tumor Cells Against Hepatocellular Carcinoma
Journal: Journal of Hepatocellular Carcinoma
DOI: 10.2147/JHC.S530997
IF: 3.4
Application: mIHC
Reactivity: Human
Publish date: 2025 Sept
-
A rationally designed cancer vaccine based on NIR-II fluorescence image-guided light-triggered remote control of antigen cross-presentation and autophagy
Journal: Acta Pharmaceutica Sinica B
DOI:
IF: 14.903
Application: IEM
Reactivity: Mouse
Publish date: 2022 Dec
Please note: All products are "FOR RESEARCH USE ONLY AND ARE NOT INTENDED FOR DIAGNOSTIC OR THERAPEUTIC USE"
Products with the same target and pathway
HLA-DR Mouse Monoclonal Antibody [10-D8]
Application: WB,IHC-P,IF-Cell
Reactivity: Human
Conjugate: unconjugated
HLA-DR Recombinant Rabbit Monoclonal Antibody [PSH26-51]
Application: WB,IF-Cell,IHC-P
Reactivity: Human
Conjugate: unconjugated
HLA-DR Recombinant Mouse Monoclonal Antibody [10-D8-R] - BSA and Azide free
Application: WB,IF-Cell,IHC-P,IF-Tissue
Reactivity: Human
Conjugate: unconjugated
HLA-DR Rabbit Polyclonal Antibody
Application: WB,IF-Cell,IHC-P,FC
Reactivity: Human,Mouse
Conjugate: unconjugated
HLA-DR Recombinant Rabbit Monoclonal Antibody [SC06-78] - BSA and Azide free
Application: WB,IF-Cell,IHC-P
Reactivity: Human
Conjugate: unconjugated
HLA-DR Recombinant Rabbit Monoclonal Antibody [PSH26-51] - BSA and Azide free
Application: WB,IF-Cell,IHC-P
Reactivity: Human
Conjugate: unconjugated
HLA-DR Recombinant Mouse Monoclonal Antibody
Application: mIHC
Reactivity: Human
Conjugate: unconjugated
HLA-DR Recombinant Mouse Monoclonal Antibody [10-D8-R]
Application: WB,IF-Cell,IHC-P,IF-Tissue,mIHC
Reactivity: Human
Conjugate: unconjugated
HLA-DR Rabbit Polyclonal Antibody
Application: WB,IF-Cell,IHC-P,FC
Reactivity: Human
Conjugate: unconjugated